LPCN Lipocine Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1535955 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.4%
TTM net income YoY-70.4%
TTM EPS YoY-22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-269.1%
Net margin-249.2%
FCF margin—
EBITDA margin-267.5%
Returns
ROE-52.9%
ROA-47.5%
ROIC (approx.)-55.3%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets8.8%
Debt / equity0.00x
Current ratio11.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio3.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.98M | $11.20M | -$2.85M | $500,000 | $16.14M |
| R&D expense | $8.58M | $7.35M | $10.18M | $8.56M | $7.67M |
| SG&A expense | $3.76M | $5.00M | $4.90M | $4.06M | $5.33M |
| Operating income | -$10.37M | -$1.16M | -$17.93M | -$12.12M | $3.15M |
| Interest expense | — | — | — | $27,098 | $203,292 |
| Pretax income | -$9.63M | $9,033 | -$16.35M | -$10.76M | -$634,199 |
| Income tax | $200 | $681 | $755 | $681 | $200 |
| Net income | -$9.63M | $8,352 | -$16.35M | -$10.76M | -$634,399 |
| EBITDA | -$10.31M | -$1.11M | -$17.90M | -$12.11M | $3.15M |
| EPS (basic) | -1.77 | — | -3.10 | -2.06 | -0.01 |
| EPS (diluted) | -1.69 | — | -3.14 | -2.15 | -0.01 |
| Weighted avg. shares (diluted) | 5.71M | 5.42M | 5.27M | 5.26M | 87.62M |
| Balance sheet | |||||
| Cash & equivalents | $5.21M | $6.21M | $4.77M | $3.15M | $2.95M |
| Short-term investments | $9.72M | $15.43M | $17.26M | $29.38M | $41.67M |
| Current assets | $16.88M | $22.32M | $22.86M | $34.14M | $46.38M |
| PP&E, net | $104,293 | $165,075 | $116,095 | $131,589 | $7,211 |
| Total assets | $17.01M | $22.51M | $23.00M | $37.54M | $52.48M |
| Current liabilities | $2.53M | $1.51M | $2.63M | $1.68M | $5.62M |
| Short-term debt | — | — | — | — | $2.31M |
| Long-term debt | — | — | — | — | $1.67M |
| Total debt | — | — | — | — | $3.98M |
| Total liabilities | $2.53M | $1.51M | $2.63M | $1.91M | $6.91M |
| Shareholders' equity | $14.48M | $21.00M | $20.37M | $35.63M | $45.57M |
| Net debt | — | — | — | — | $1.03M |
| Shares outstanding | 6.16M | 5.35M | 5.32M | 5.23M | 88.29M |
| Cash flow statement | |||||
| Operating cash flow | -$9.76M | -$1.22M | -$11.87M | -$11.97M | -$4.41M |
| Capital expenditure | — | $90,086 | $13,167 | $133,831 | $7,591 |
| Free cash flow | — | -$1.31M | -$11.88M | -$12.10M | -$4.42M |
| Investing cash flow | $5.89M | $2.45M | $13.08M | $14.29M | -$43.78M |
| Financing cash flow | $2.87M | $209,340 | $404,567 | -$2.13M | $26.92M |
| Depreciation & amortization | $60,782 | $41,106 | $28,661 | $9,453 | $380 |
| Stock-based compensation | $242,497 | $408,551 | $654,438 | $636,140 | $603,946 |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.